TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.

ABSTRACT: Genetically engineered T cell therapy can induce remarkable tumor responses in hematologic malignancies. However, it is not known if this type of therapy can be applied effectively to epithelial cancers, which account for 80-90% of human malignancies. We have conducted a first-in-human, phase 1 clinical trial of T cells engineered with a T cell receptor targeting HPV-16 E7 for the treatment of metastatic human papilloma virus-associated epithelial cancers (NCT02858310). The primary endpoint was maximum tolerated dose. Cell dose was not limited by toxicity with a maximum dose of 1 × 10¹¹ engineered T cells administered. Tumor responses following treatment were evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) guidelines. Robust tumor regression was observed wi

SUBMITTER: Nagarsheth NB 

PROVIDER: S-EPMC9620481 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature